Monitor for prospectus supplements indicating actual takedowns under the shelf. Any announced offering will likely be heavily dilutive given the micro-cap float. The going-concern qualification and zero-revenue profile suggest this is a distress-driven capital raise rather than opportunistic. Watch for ATM or registered direct offerings that could pressure the stock.
Price Chart
Executive Summary
NanoViricides filed a universal shelf registration statement on Form S-3 to register up to $50 million in securities (common stock, preferred stock, debt, warrants, rights, units) for potential future sale. The company is a clinical-stage biotech with no revenue and an auditor's going-concern qualification, making this a likely capital-raising vehicle to fund Phase II trials and operations. The shelf represents a significant potential dilution risk relative to the $32M market cap.
Key Financial Metrics
Key Facts
- Shelf registration of up to $50,000,000 in securities (common, preferred, debt, warrants, rights, units).
- Market cap is approximately $32M; the shelf size is ~156% of current market cap.
- Non-affiliate public float is approximately $35.5M (22.98M shares outstanding, ~626K held by affiliates, price $1.59).
- Company is a clinical-stage biotech with no customers, products, or revenues.
- Auditor's report includes an explanatory paragraph about substantial doubt regarding going concern.
- Proceeds intended for general corporate purposes including working capital and clinical trial funding.
- NV-387 is Phase II-ready; company is preparing MPox and Viral ARI/SARI trials.
- Facilities (18,000 sq ft) are owned free and clear of mortgage/debt.
Financial Impact
Potential dilution of up to ~156% of current market cap ($50M shelf vs $32M market cap). At the $1.59 reference price, full issuance would add ~31.4M shares, diluting existing holders by ~58%.
Risk Factors
- Massive potential dilution: $50M shelf is 156% of current $32M market cap.
- Going-concern qualification from auditor indicates high risk of capital exhaustion without this raise.
- Zero revenue and no approved products; clinical-stage risk with no guarantee of Phase II success.
- Stock price below $2.00 on NYSE American may trigger continued listing standards risk if it stays low.
- No specific use of proceeds beyond general corporate purposes — no catalyst tied to the filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001104659-26-071007 |
| Document: tm2616485d1_ex-filingfees.htm | 0001104659-26-071007 |
| Document: tm2616485d1_ex5-1.htm | 0001104659-26-071007 |
| Document: tm2616485d1_ex23-2.htm | 0001104659-26-071007 |
| Document: 0001104659-26-071007-index-headers.html | 0001104659-26-071007 |
| Document: 0001104659-26-071007-index.html | 0001104659-26-071007 |
| Document: 0001104659-26-071007.txt | 0001104659-26-071007 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 424B5 | $1.51 | awaiting T+60 | — | $1.36 (−9.93%) |
Oct 8, 2026 18d ago | DEF 14A | $1.31 | awaiting T+60 | — | $1.36 (+3.82%) |
Jul 27, 2026 13w ago | 424B5 | $1.54 $1.48 | ▲ +3.90% | ▲ +7.95% | $1.36 (+11.69%) |
Jul 27, 2026 13w ago | 424B5 | $1.54 $1.48 | ▼ −3.90% | ▼ −7.95% | $1.36 (−11.69%) |
Jun 29, 2026 17w ago | EFFECT | $1.37 $1.51 | ▼ −10.22% | ▼ −6.60% | $1.36 (+0.73%) |
Jun 16, 2026 18w ago | EFFECT | $1.36 $1.02 | ▼ −25.00% | ▼ −26.86% | $1.36 (+0.00%) |
Jun 15, 2026 18w ago | S-3 | $1.36 $1.02 | ▼ −25.00% | ▼ −26.86% | $1.36 (+0.00%) |
Jun 5, 2026 20w ago | S-3 | $1.43 $1.17 | ▲ +18.18% | ▲ +21.69% | $1.36 (+4.90%) |
May 18, 2026 23w ago | 424B5 | $1.51 $1.37 | ▲ +9.27% | ▲ +14.12% | $1.36 (+9.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers